Trametinib Presents Potential New Standard-of-Care for Low-Grade Serous Ovarian Carcinoma
February 7th 2022Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.
Read More
New Research Finds Patient Out-of-Pocket Spending Increased for Hepatitis B Medication
February 4th 2022During that time period, patients with high-deductible health plans spent on average $133 per 30-day supply, a cost threshold associated with a more than 50% rate of prescription abandonment, according to the researchers.
Read More
Expert Discusses Positive Outcomes Associated With Oncology Care Model
February 4th 2022Stuart Staggs, senior director of strategic programs at McKesson, discussed the encouraging metrics associated with use of the Oncology Care Model (OCM) sponsored by the Centers for Medicare and Medicaid Services.
Watch